Milestone Scientific Appoints Jason Papes as Senior Vice President, Global Head of Sales and Marketing
Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments, has appointed Jason Papes as Senior Vice President, Global Head of Sales and Marketing. Papes brings over 30 years of healthcare industry experience, notably as Founder of TEN20 Medical Distribution and executive positions at Stryker Imaging and Brainlab.
The appointment comes at a crucial time as MLSS advances the commercial rollout of its CompuFlo® Epidural System, which recently received Medicare Part B payment rates under CPT® code 0777T. The company is also expanding its dental segment through the STA Single Tooth Anesthesia® System. Papes will be instrumental in scaling both platforms and implementing market access strategies.
Milestone Scientific (NYSE:MLSS), sviluppatore di strumenti computerizzati per la somministrazione di farmaci, ha nominato Jason Papes come Senior Vice President, Global Head of Sales and Marketing. Papes vanta oltre 30 anni di esperienza nel settore sanitario, in particolare come fondatore di TEN20 Medical Distribution e in ruoli dirigenziali presso Stryker Imaging e Brainlab.
La nomina avviene in un momento cruciale, mentre MLSS sta avanzando nel lancio commerciale del suo CompuFlo® Epidural System, che ha recentemente ottenuto le tariffe di pagamento Medicare Parte B sotto il codice CPT® 0777T. L'azienda sta inoltre ampliando il segmento dentale tramite il sistema STA Single Tooth Anesthesia®. Papes sarà fondamentale per l'espansione di entrambe le piattaforme e per l'implementazione delle strategie di accesso al mercato.
Milestone Scientific (NYSE:MLSS), desarrollador de instrumentos informatizados para la administración de medicamentos, ha nombrado a Jason Papes como Vicepresidente Senior y Director Global de Ventas y Marketing. Papes aporta más de 30 años de experiencia en la industria sanitaria, destacando como fundador de TEN20 Medical Distribution y en cargos ejecutivos en Stryker Imaging y Brainlab.
El nombramiento llega en un momento crucial, ya que MLSS avanza en el lanzamiento comercial de su CompuFlo® Epidural System, que recientemente recibió las tarifas de pago Medicare Parte B bajo el código CPT® 0777T. La empresa también está expandiendo su segmento dental a través del sistema STA Single Tooth Anesthesia®. Papes será clave para escalar ambas plataformas e implementar estrategias de acceso al mercado.
Milestone Scientific (NYSE:MLSS)는 컴퓨터화된 약물 전달 기기 개발업체로서 Jason Papes를 글로벌 영업 및 마케팅 총괄 수석 부사장으로 임명했습니다. Papes는 TEN20 Medical Distribution 창립자이자 Stryker Imaging 및 Brainlab에서의 임원 경력을 포함해 30년 이상의 의료 산업 경험을 보유하고 있습니다.
이번 임명은 MLSS가 최근 CPT® 코드 0777T에 따른 Medicare Part B 지급률을 획득한 CompuFlo® Epidural System의 상업적 출시를 앞두고 있는 중요한 시기에 이루어졌습니다. 또한 회사는 STA Single Tooth Anesthesia® 시스템을 통해 치과 부문도 확장하고 있습니다. Papes는 두 플랫폼의 확장과 시장 접근 전략 실행에 핵심적인 역할을 할 것입니다.
Milestone Scientific (NYSE:MLSS), développeur d'instruments informatisés pour l'administration de médicaments, a nommé Jason Papes au poste de Senior Vice President, Global Head of Sales and Marketing. Papes apporte plus de 30 ans d'expérience dans le secteur de la santé, notamment en tant que fondateur de TEN20 Medical Distribution et à des postes de direction chez Stryker Imaging et Brainlab.
Cette nomination intervient à un moment crucial alors que MLSS progresse dans le déploiement commercial de son CompuFlo® Epidural System, qui a récemment obtenu les taux de remboursement Medicare Partie B sous le code CPT® 0777T. L'entreprise étend également son segment dentaire grâce au système STA Single Tooth Anesthesia®. Papes jouera un rôle clé dans le développement des deux plateformes et la mise en œuvre des stratégies d'accès au marché.
Milestone Scientific (NYSE:MLSS), ein Entwickler computergestützter Arzneimittelabgabegeräte, hat Jason Papes zum Senior Vice President und Global Head of Sales and Marketing ernannt. Papes bringt über 30 Jahre Erfahrung in der Gesundheitsbranche mit, insbesondere als Gründer von TEN20 Medical Distribution sowie in Führungspositionen bei Stryker Imaging und Brainlab.
Die Ernennung erfolgt zu einem entscheidenden Zeitpunkt, da MLSS die kommerzielle Markteinführung seines CompuFlo® Epidural System vorantreibt, das kürzlich Medicare Part B Zahlungssätze unter dem CPT®-Code 0777T erhalten hat. Das Unternehmen erweitert zudem seinen Dentalbereich durch das STA Single Tooth Anesthesia® System. Papes wird eine Schlüsselrolle bei der Skalierung beider Plattformen und der Umsetzung von Marktzugangsstrategien spielen.
- Appointment of experienced executive with 30+ years in healthcare and medical technology
- Medicare Part B payment rates established for CompuFlo® System under CPT® code 0777T
- Commercial expansion progressing with initial activity from commercial insurers
- Strategic focus on both medical (CompuFlo) and dental (STA) segments for growth
- None.
Brings over 30 years of experience in scaling commercial operations across healthcare and medical technology sectors
ROSELAND. N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately.
Mr. Papes brings more than three decades of experience in sales, marketing, and business development within the healthcare industry, including leadership roles at large-cap medical technology companies and successful entrepreneurial ventures. His expertise spans orthopedics, neurology, pain management, and digital imaging, with a track record of building high-performance teams, establishing national and international distribution networks, and driving strategic growth initiatives.
Most recently, Mr. Papes served as Founder and Managing Partner of TEN20 Medical Distribution, a healthcare sales organization focused on spinal implants, intraoperative neuromonitoring, and clinical research. Under his leadership, the company became one of the largest distributorships for Orthofix’s bone growth stimulators and bone graft products, earning multiple Distributor of the Year honors. He also led several affiliated ventures through successful exits, including Neuro-Pro Monitoring and TEN20 Living Assistance.
Prior to founding TEN20, Mr. Papes held executive positions at Stryker Imaging, where he led a
Mr. Papes joins Milestone at an important inflection point in the Company’s commercial rollout of the CompuFlo® Epidural System. The Company has made meaningful progress in establishing procedural payment pathways, including the assignment of Medicare Part B payment rates under CPT® code 0777T across several jurisdictions, along with initial activity from commercial insurers. These developments mark a critical step in supporting provider adoption and integrating CompuFlo into routine clinical practice.
In parallel, Milestone continues to advance growth initiatives within its dental segment, with a focus on increasing adoption of its STA Single Tooth Anesthesia® System among dental offices, group practices, and institutional providers. Mr. Papes will play a key role in scaling both platforms to support the Company’s broader commercial objectives.
Eric Hines, Chief Executive Officer of Milestone Scientific, commented, “Jason’s extensive leadership experience and deep understanding of the provider and payer landscape make him a strong addition to our team. His ability to scale commercial organizations and build market access strategies aligns with our next phase of growth. We look forward to his contributions as we expand adoption of the CompuFlo system across hospital and outpatient settings.”
Jason Papes added: “Milestone Scientific has developed a truly differentiated platform with potential to transform how epidural and dental procedures are delivered. I’m excited to join a team committed to innovation, patient safety, and commercial execution. I look forward to working alongside the leadership team to broaden our reach and drive value for patients, providers, and shareholders.”
Mr. Papes earned a Bachelor of Science in Biology with a minor in Chemistry from Wake Forest University and holds an International MBA from Rome Business School. He has also completed executive programs in corporate strategy and complex sales.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient, and increase the overall patient comfort and safety. The Company leverages its proprietary DPS Dynamic Pressure Sensing Technology® platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetics. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2024. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
FAQ
Who is the new SVP of Global Sales and Marketing at Milestone Scientific (NYSE:MLSS)?
What are Jason Papes' notable previous positions before joining Milestone Scientific?
What recent Medicare development has Milestone Scientific achieved for its CompuFlo System?
What are the main products Milestone Scientific is currently focusing on?
